Literature DB >> 18220288

Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis.

Maria Serena Longhi1, Francesca Meda, Pengyun Wang, Marianne Samyn, Giorgina Mieli-Vergani, Diego Vergani, Yun Ma.   

Abstract

UNLABELLED: CD4+CD25+ regulatory T cells (T-regs) are central to the maintenance of immune tolerance and represent an immune intervention candidate in autoimmune hepatitis (AIH), a condition characterized by impaired T-reg number and function. We investigated whether T-regs can be expanded from the existing CD4+CD25+ T cell pool and generated de novo from CD4+CD25- T cells in AIH patients and healthy controls. Purified CD4+CD25+ and CD4+CD25- T cells from 24 patients with type 1 AIH and 22 healthy controls were cultured for up to 5 weeks with anti-CD3/anti-CD28 T cell expander and high-dose interleukin-2 (IL-2). Cell phenotypes, suppressor ability, forkhead winged/helix transcription factor box P3 (FOXP3) gene, and protein expression were assessed weekly by cytofluorimetry, proliferation assay, real-time polymerase chain reaction (PCR), and immunoblot. During culture, the number of CD4+CD25+ T cells derived from the existing T-reg pool (expanded T-regs) and generated de novo from CD4+CD25- T cells (newly generated T-regs) increased constantly up to week 4 in both healthy controls and, to a lesser extent, in AIH patients. Expanded T-regs retained conventional T-reg phenotype and, compared with baseline, demonstrated more vigorous suppressive function and increased FOXP3 gene and protein expression. Newly generated T-regs not only acquired T-reg phenotype but underwent greater growth and were more resistant to apoptosis than expanded T-regs. Their suppressive function augmented throughout culture, reaching a peak at week 4, preceded by a peak FOXP3 gene and protein expression at week 2. Suppressor function and FOXP3 expression of both expanded and newly generated T-regs were higher in normal controls than in AIH patients.
CONCLUSION: Functionally enhanced T-regs can be expanded and generated de novo in patients with AIH. This finding may assist in reconstituting impaired immune regulation and restoring peripheral tolerance through T-reg infusion in this condition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18220288     DOI: 10.1002/hep.22071

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  34 in total

Review 1.  Advances in the current treatment of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-04-03       Impact factor: 3.199

2.  Enhanced suppressive function of regulatory T cells from patients with immune-mediated diseases following successful ex vivo expansion.

Authors:  Tinghua Cao; Sally E Wenzel; William A Faubion; Gregory Harriman; Li Li
Journal:  Clin Immunol       Date:  2010-05-15       Impact factor: 3.969

Review 3.  Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-01-27       Impact factor: 3.199

4.  A novel "humanized mouse" model for autoimmune hepatitis and the association of gut microbiota with liver inflammation.

Authors:  Muhammed Yuksel; Yipeng Wang; Ningwen Tai; Jian Peng; Junhua Guo; Kathie Beland; Pascal Lapierre; Chella David; Fernando Alvarez; Isabelle Colle; Huiping Yan; Giorgina Mieli-Vergani; Diego Vergani; Yun Ma; Li Wen
Journal:  Hepatology       Date:  2015-08-25       Impact factor: 17.425

Review 5.  Cutting edge issues in autoimmune hepatitis.

Authors:  Diego Vergani; Giorgina Mieli-Vergani
Journal:  Clin Rev Allergy Immunol       Date:  2012-06       Impact factor: 8.667

Review 6.  Primary biliary cirrhosis and liver transplantation.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara
Journal:  Intractable Rare Dis Res       Date:  2012-05

Review 7.  Autoantibody-negative autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-12-21       Impact factor: 3.199

8.  Immune-mediated bile duct injury: The case of primary biliary cirrhosis.

Authors:  Carlo Selmi; Andrea Affronti; Laura Ferrari; Pietro Invernizzi
Journal:  World J Gastrointest Pathophysiol       Date:  2010-10-15

Review 9.  Cell mediators of autoimmune hepatitis and their therapeutic implications.

Authors:  Aldo J Montano-Loza; Albert J Czaja
Journal:  Dig Dis Sci       Date:  2014-12-09       Impact factor: 3.199

Review 10.  Autoimmune hepatitis.

Authors:  Diego Vergani; Maria Serena Longhi; Dimitrios P Bogdanos; Yun Ma; Giorgina Mieli-Vergani
Journal:  Semin Immunopathol       Date:  2009-06-17       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.